Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.

MLA

Bornhäuser, Martin, et al. “Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.” JAMA Oncology, vol. 9, no. 4, Apr. 2023, pp. 519–26. EBSCOhost, https://doi.org/10.1001/jamaoncol.2022.7605.

APA

Bornhäuser, M., Schliemann, C., Schetelig, J., Röllig, C., Kramer, M., Glass, B., Platzbecker, U., Burchert, A., Hänel, M., Müller, L. P., Klein, S., Bug, G., Beelen, D., Rösler, W., Schäfer-Eckart, K., Schmid, C., Jost, E., Lenz, G., Tischer, J., … Stelljes, M. (2023). Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial. JAMA Oncology, 9(4), 519–526. https://doi.org/10.1001/jamaoncol.2022.7605

Chicago

Bornhäuser, Martin, Christoph Schliemann, Johannes Schetelig, Christoph Röllig, Michael Kramer, Bertram Glass, Uwe Platzbecker, et al. 2023. “Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.” JAMA Oncology 9 (4): 519–26. doi:10.1001/jamaoncol.2022.7605.